key: cord-1023117-1ns2yogp
authors: Martin, Sophie; Heslan, Christopher; Jégou, Gwénaële; Eriksson, Leif A.; Le Gallo, Matthieu; Thibault, Vincent; Chevet, Eric; Godey, Florence; Avril, Tony
title: SARS-CoV-2 integral membrane proteins shape the serological responses of COVID-19 patients.
date: 2021-09-29
journal: iScience
DOI: 10.1016/j.isci.2021.103185
sha: 69852f69dbbf14ea7094806285f7cb73dfca900b
doc_id: 1023117
cord_uid: 1ns2yogp

SARS-CoV-2 pandemic has elicited a unique mobilization of the scientific community to develop efficient tools to understand and combat infection. Like other coronavirae, SARS-CoV-2 hijacks host cell secretory machinery to produce viral proteins that compose the nascent virions; including Spike (S), Envelope (E) and Membrane (M) proteins, the most exposed transmembrane proteins to the host immune system. As antibody response is part of the anti-viral immune arsenal, we investigate the immunogenic potential of S, E and M using a human cell-based system to mimic membrane insertion and N-glycosylation. Both S and M elicit specific Ig production in SARS-CoV-2 patients. Patients with moderate and severe diseases exhibit elevated Ig responses. Finally, reduced Ig binding was observed with Spike G614 compared to D614 variant. Altogether, our assay points towards an unexpected immune response against M and represents a powerful tool to test humoral responses against actively evolving SARS-CoV-2 variants and vaccine effectiveness.

The current COVID-19 pandemic has triggered unprecedented collective research efforts from the scientific community to better understand the disease and its cellular and molecular mechanisms, to identify efficient therapeutic drugs for taking care of infected patients with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and to develop vaccines for protecting the whole population from the infection (Hu et al., 2020 , Poland et al., 2020 , Sicari et al., 2020 . One of the initial challenges in the fight against this virus was to rapidly detect SARS-CoV-2 infected patients to limit the propagation of the virus through isolation (Ravi et al., 2020) . Another challenge was to better understand the global antibody responses against SARS-CoV-2 proteins in patients (Poland et al., 2020, Zohar and Alter, 2020) .

Among the anti-viral immune responses elicited in infected patients, immunoglobulin (Ig) responses against viral transmembrane proteins expressed at the surface of the virus envelope are important for generating antibodies that limit virus propagation. This occurs by preventing interactions with host cells, i.e. production of neutralizing antibodies that block the binding of the viral transmembrane Spike protein to its receptor angiotensin-converting enzyme 2 (ACE2) expressed by infected host cells (Poland et al., 2020 , Lan et al., 2020 , Hoffmann et al., 2020 , Zohar and Alter, 2020 . These anti-virus antibodies are also key mediators to trigger antibody-dependent immune responses such as the complementdependent cytotoxicity as part of the humoral response (Zohar and Alter, 2020) or the antibody-dependent cellular cytotoxicity mediated by immune cells harboring Fc receptors such as NK lymphocytes, macrophages and granulocytes to allow phagocytosis and destruction of the virus (Zohar and Alter, 2020) .

Some of these cellular actors such as macrophages and neutrophils could also contribute to the aggravation of the disease by releasing chemokines and cytokines that enhance inflammatory cascades described as 'cytokine storms' leading to lesions of infected tissues; although the involvement of the antibody-dependent mechanisms still need to be confirmed in COVID-19 patients (Zohar and Alter, 2020) . Most of the serological assays developed against SARS-CoV-2 are based on the recognition of the viral transmembrane Spike protein and the nucleocapsid protein N, considered as major targets of antibody responses (Grzelak et al., 2020 , Ripperger et al., 2020 . Besides the viral Spike protein, little is known on Ig responses towards the others viral transmembrane proteins E and M also directly exposed to the host immune system. J o u r n a l P r e -p r o o f 4 Spike (S), envelope (E) and membrane (M) are integral membrane proteins that transit through the host cells' endoplasmic reticulum (ER), the ER-Golgi intermediate compartment (ERGIC) and most likely the Golgi complex. In the ER, these proteins are N-glycosylated, folded, and assembled in the ERGIC for virus budding and release (Sicari et al., 2020) . This maturation process is key for proper viral protein functions. For instance, Spike N-linked glycosylation is required for virus entry into the host cells impacting directly on Spike stability during its synthesis instead of its binding ability to the ACE2 receptor . These modifications might be also key for antibody recognition.

In the present study, we relied on an experimental system that recapitulates protein modifications acquired through the host cells' secretory pathway to explore the antibody responses of SARS-CoV-2 infected patients. We found that S and M proteins (but not E) exhibited antigenic domains recognized by IgG, IgM and IgA in SARS-CoV-2 infected patients.

High levels of Ig responses were observed in COVID-19 patients with moderate and severe forms of the disease. Finally, SARS-CoV-2 Spike D614 and G614 variants were compared, showing reduced Ig binding on the Spike G614 variant. Altogether, this study underlines the necessity of considering the mammalian cellular system to better characterize the serological status of COVID-19 patients.

J o u r n a l P r e -p r o o f

As viral transmembrane protein recognition is part of the anti-SARS-CoV-2 immune response, we developed a mammalian cell-based serological assay using SARS-CoV-2 S, E and M expressing human embryonic kidney (HEK) cells to mimic integral membrane protein maturation found at the surface of viral particles ( Figure 1A) . HEK cells were transiently transfected with genes encoding for SARS-CoV-2 S, E and M proteins in tandem with either two Strep-Tag II motifs (Gordon et al., 2020) or a FLAG tag (hereafter named Sf). Forty-eight hours post-transfection, total and surface expression of S, E and M was confirmed using both western blotting with HRP-conjugated StrepTactin ( Figure 1B) , anti-FLAG or anti-Spike antibodies; and flow cytometry using BV650-conjugated streptavidin, respectively ( Figure 1C ).

Cell surface expression of S was also confirmed using flow cytometry using an anti-Spike antibody ( Figure 1D ). The proportion of positive cells and the expression levels of viral proteins were similar between experiments and when viral proteins were compared (Figure 1C and 1D). To validate the binding of anti-SARS-CoV-2 IgG, IgM and IgA subtypes to HEK cells expressing viral transmembrane proteins, we used two sera from SARS-CoV-2 infected patients (COVID+ and CTR#4, the latter being distributed by SeroBio as a validation tool for diagnostic laboratories) and one serum from a healthy donor (PRECOV obtained before January 2020) as a negative control. Sera were incubated with non-permeabilized HEK cells and Ig binding was detected using secondary antibodies specific for each Ig subtype. Nonspecific binding was determined using non-transfected HEK cells. IgG, M and A binding was observed on S-expressing HEK cells using sera form SARS-CoV-2 infected patients in a concentration-dependent manner, whereas no Ig binding was detected using the healthy serum (Figures 1E and 1F) . These results indicate that S is expressed at the surface of HEK cells and can be detected by anti-S antibodies from COVID+ patients.

A cohort of 129 patients was next tested in our serological assay including sera from i) heathy/asymptomatic donors obtained before (n=38) and after January 2020 (n=26), ii) patients infected with non-SARS-CoV-2 coronavirus (n=5), iii) patients suffering from hyperimmunoglobulin M syndromes (n=5), iv) patients with symptoms similar to those observed in J o u r n a l P r e -p r o o f 6 COVID+ patients (i.e. anosmia, cough, fatigue, fever) (n=4), and v) patients previously infected with SARS-CoV-2 (as confirmed by PCR, n=51) and developing mild (patients who did not need hospitalization, n=22), moderate (hospitalized patients treated with oxygen therapy <5L, n=14) and severe (hospitalized patients in ICU with oxygen therapy >5L or intubated, n=15) forms of the COVID-19 disease (Tables 1 and S1 ). The time between the PCR tests (or the first symptoms) and the blood sampling were similar between the groups of COVID-19 patients (between 15 and 25 days; Figure S1A ). Our results were comparable to those obtained with assays developed for diagnostic laboratories by Beckman (IgG anti-Spike) and Roche (Ig anti-N protein), showing 93% and 89% concordance, respectively ( Figure S1B ). No Ig binding to S, E and M proteins was observed using i) control sera including those obtained before January 2020, ii) sera from patients infected with other coronaviruses or iii) sera from patients suffering from hyper-immunoglobulin M syndromes (Figures 2A, 2B and S1C). The positive threshold was therefore set using these control sera. Anti-Spike IgG, IgM and IgA were detected in sera from COVID+ patients as well as in those from patients with COVID-19associated symptoms. Anti-Spike Ig titers were higher in patients with moderate and severe forms of the disease compared to mild forms (Figures 2A and 2C) . Anti-E Ig were never detected in any of the tested sera ( Figure S1C) . Importantly, anti-M Ig were also observed at a higher level in patients with severe forms of the disease (Figures 2B and 2C) . 

Our assay recapitulating viral protein modification and insertion in a membrane was validated using COVID-19 patients' sera and yielded results comparable to those obtained with commercially available tests ( Figure S1B) . However, the latter tests use the Spike D614 variant as antigen and it is well established that most European patients until the end of 2020 were mainly infected by SARS-CoV-2 expressing Spike G614 (e.g. French patients were exclusively exposed to Spike G614 variant from March to December 2020 (Korber et al., 2020) ). This might lead to biases in data interpretation. Hence, we sought to investigate potential differences in terms of antibody responses using our assay. First, we compared the structural properties of the Spike D614 and G614 variants. As a very useful tool to provide overviews of large protein complexes, cryo-electron microscopy has been extensively used to describe SARS-CoV-2 Spike J o u r n a l P r e -p r o o f 7 structural features (Benton et al., 2021 , Gobeil et al., 2021 . One limitation of such an approach is the low resolution in terms of atomic details. We performed a molecular modeling focusing on the beta-sheet rich domain containing D/G614 of chain A (yellow), and its interaction with the patch T824-E865 on chain B (golden), squared in Figure   3A . D614 (chain A) forms an inter-protomeric salt bridge to K854 (chain B) (Figure 3B top) . In the same region, there is also an inter-protomeric salt bridge between R646 (chain A)  E865 (chain B). Using the model with the D614G mutant of 6BZ5, we observed that K854 (chain B) remains pointing towards protomer A, and forms a H-bond to the carbonyl backbone of G614 (i.e. a weaker and more strained interaction than in the case of D614 (Figure 3B, bottom) ).

The second salt bridge R646 (chain A)  E865 (chain B) is still retained. Looking at the electrostatic and hydrophobic properties of the area in protomer A, we observed that the domain side interacting with protomer B is largely nonpolar, except for D614 and R646

( Figures 3C and 3D , top). In contrast, the electrostatic interaction is considerably weaker in the G614 variant, and essentially only retained by R646 protruding towards E854 (chain B) ( Figures 3C and 3D, bottom) . The sequences at the domain interfaces consist largely of nonpolar residues, and the change from D614 to G614 clearly impacts on the overall polarity of the protomer A interaction area. We also note that in the G614 variant, the loop region after K854 of protomer B (golden) is bending further away from protomer A, than what is observed in the D614 variant. Analysis of the surfaces of protomer B in the interface also illustrates the difference in interactions between the two protomers. In particular the non-polar region of protomer B is protruding towards protomer A between D614 and R646 in the D614 variant, but is in contrast pushed back/out in the G614 variant ( Figure S2E ). In addition the segment around K854 is in G614 clearly rotated away from protomer A. In the region close to E865 of protomer B, an increased exposure of hydrophilic/polar residues towards the solvent (better seen in the lipophilicity surfaces) was observed. These analyses indicate that the G614D mutation might alter the global structure of the protein and therefore the antigenic response.

Anti-Spike Ig response was therefore re-evaluated using sera from COVID+ patients and anti-Spike D614 and G614 variants expressing cells. Expression of the Spike variants in HEK cells was validated as previously ( Figures S2B-D) . Similar expression levels of Spike D614 and G614 variants were found at the cell surface (Figures S2C and S2D) . Sera from COVID+ patients were then tested on both cell systems and a lower anti-S IgG, IgM and IgA binding to Spike G614 was observed in most of the patients than that observed for binding to the D614 variant J o u r n a l P r e -p r o o f 8 ( Figure 3E) . Only a small proportion of those patients (less than 15%) displayed similar Ig responses against the two Spike variants (Figures 3E and 3F) . When compared to assays developed for diagnostic laboratories by Beckman (IgG anti-Spike) and Roche (Ig anti-N protein), respectively 90% and 95% concordance were observed with our cell-based assay using G614 variant ( Figure S2E ). Hence our experimental system allows for discrimination between anti-S D614 vs. G614 Ig signals likely due to the advantage of using transmembrane inserted Spike following complex folding and post-translational modifications.

J o u r n a l P r e -p r o o f 9

Using a mammalian cell-based assay with the SARS-CoV-2 integral membrane proteins S, E and M (Figure 1) , we identified antibody responses against both S and M proteins in COVID+ patients but not against the transmembrane viral protein E. Higher anti-S and -M Ig production correlated with symptom severity in hospitalized COVID+ patients (Figure 2) . Furthermore, whereas French patients were exclusively exposed to SARS-CoV-2 expressing the Spike G614 variant until December 2020, reduced IgG, IgM and IgA binding was observed on Spike G614 compared to that observed for the D614 variant (Figure 3) . Overall, this study underlines the importance of using antigens respecting viral protein constraints to investigate antibody responses against SARS-CoV-2 transmembrane proteins.

Most of the diagnostic tests currently used to detect the antibody response against SARS-CoV-2 target the viral proteins S and N as both were initially found to be expressed abundantly and exhibit substantial antigenicity (Algaissi et al., 2020 , Amanat et al., 2020 , Lee et al., 2020 , Houlihan and Beale, 2020 , Rikhtegaran Tehrani et al., 2020 , La Marca et al., 2020 .

One of the drawbacks associated with these assays is the use of recombinant proteins produced in prokaryotic systems that only include fragments of Spike (e.g. S1 subunit or RBD domain (Algaissi et al., 2020 , Amanat et al., 2020 , Lee et al., 2020 , Houlihan and Beale, 2020 , Rikhtegaran Tehrani et al., 2020 , La Marca et al., 2020 ). Recent structural analyses have revealed that the structural integrity of the full-length Spike multimers (trimers, dimers of trimers and more) is important to better understand its immunogenic potential (Bangaru et al., 2020) . As the virus hijacks the host secretory machinery to produce nascent viral particles in infected cells (Sicari et al., 2020) , we designed a reliable serological assay using mammalian cells that express full-length SARS-CoV-2 transmembrane proteins S, M and E, the most exposed to the host immune system. Such a system allows for proper folding and posttranslational modifications of the viral proteins (Sicari et al., 2020) . These modifications include for instance disulfide bond formation and N-glycosylation thus leading to native structural features.

Recent studies have mapped the regions of SARS-CoV-2 proteins recognized by antibodies from COVID-19 patients using proteome microarrays (Krishnamurthy et al., 2020 . Antibody production was detected against peptides derived from the structural proteins Spike (S1, S2 and RBD domains), N and M and from the accessory protein ORF3a. Interestingly, we are able to demonstrate for the first time the J o u r n a l P r e -p r o o f 10 occurrence of an antibody response in COVID+ patients against the entire M protein using our cell-based serological assay, thereby confirming results observed in proteome microarrays in a more physiological context (Krishnamurthy et al., 2020 .

Higher Ig binding was observed in hospitalized COVID+ patients with moderate and severe forms of the disease. Of note, Ig response against the M protein was always observed in patients that also exhibited an anti-Spike Ig response.

One additional advantage of the assay developed herein, is the possibility to quickly adapt to express new envelope protein variants. As an example, we compared the Ig responses against the Spike variants D614 and G614. To our surprise, Spike G614 displayed a lower Ig binding capacity compared to D614. Structural analyses revealed differences in electrostatic and hydrophobic surfaces between the Spike variants that could impact on Ig affinity, as discussed previously (Benton et al., 2021) . Interestingly, D614G is located near the 615 to 635 flexible loop leading to a salt bridge between D/G614 of one protomer and K854 on the neighboring protomer, possibly affecting the global structure of the Spike trimer , increasing the RBD 'up' state and S1/S2 proteolysis (Gobeil et al., 2021) . Of note, no difference in Ig binding levels has previously been observed in ELISA-based assays (Klumpp-Thomas et al., 2020) . The discrepancy observed with our study could be linked to the type of serological assay used; ELISA versus cell-based assays could exacerbate these protein structural differences. Intriguingly, French COVID-19 patients analyzed in this study were exclusively exposed to SARS-CoV-2 expressing Spike G614 variant, suggesting that the mutation does not reduce the antigenicity against Spike but instead reduce IgG, IgM and IgA binding. One could speculate that this mutation gave a selective advantage to the European SARS-CoV-2 strain by limiting the antibody response in infected patients, and therefore allowing a larger virus spreading. Many new SARS-CoV-2 strains associated with Spike substitutions have recently emerged (e.g. as observed for variants from Brazil, United-Kingdom and South-Africa) with increased infectivity (Leung et al., 2021 , Tegally et al., 2020 , Paiva et al., 2020 , Gröhs Ferrareze et al., 2021 . These new strains also display several mutations in other viral genes encoding for structural and accessory proteins. However, very few mutations were described for M so far (Mercatelli and Giorgi, 2020, Laamarti et al., 2020) , suggesting that anti-M Ig responses described in this study could be conserved across the different SARS-CoV-2 lineages. If anti-M antibodies effectively reduce SARS-CoV-2 infectivity, J o u r n a l P r e -p r o o f 11 the low variation burden on this protein might also reveal an efficient tool for vaccine development.

In contrast to the other SARS-CoV-2 transmembrane proteins Spike and M, no antibody against the protein E was detected in our assay. This could be explained by the fact that E might not be expressed at the surface of the cells or that it may not expose enough antigenic regions to mount a potent immune response. Previous studies indicate that SARS-CoV-2 derived E protein seems to be mainly localized in the host cells at the ER, ERGIC and/or Golgi compartments although the precise localization is still debated (Satarker and Nampoothiri, 2020, Miserey-Lenkei et al., 2020) . Furthermore, a recent study unveils the impact of the addition of tags on E protein localization within the host cells, in particular at the C-terminus position (near the DLLV motif) leading to its retention into the ER (Pearson et al., 2021) . We could not however exclude that our construct encoding for a viral E protein tagged with two Strep-Tag motifs may also lead to its retention within the host cells. Another limit of our study lies in the fact that viral S, E and M proteins were expressed individually and not simultaneously; the latter possibly leading to structural changes and variation in the obtained before January 2020 was used as a negative control. The binding of IgG, IgM and IgA immunoglobulins were analyzed by flow cytometry using secondary antibodies specific for each Ig subtype. Representative flow cytometry histograms were shown for Spike in (E) and results were presented as specific Ig binding relative to HEK cells (F). Statistical analysis: oneway ANOVA test comparing S, E and M conditions.

using the SARS-CoV-2 serological assay described in Figure 1 . Control sera were obtained from healthy donors and collected before January 2020 (CTR, n=38); and from patients infected with other coronaviruses (n=5) or patients with hyperimmunoglobulin M syndrome (n=5) (included in CTR2, n=10). Sera collected after January 2020 were obtained from donors without symptoms (no symptom, n=26); with symptoms related to SARS-CoV-2 infection (symptoms, n=4); and from patients positive for SARS-CoV-2 infection (COVID+) and developing mild (blue, n=22), moderate (green, n=14) and severe (orange, n=15) forms of COVID-19. Specific binding of IgG (circles), IgM (squares) and IgA (diamonds) were represented and thresholds (grey boxes) were obtained with the basal levels of Ig binding from control J o u r n a l P r e -p r o o f 14 sera. Statistical analysis: unpaired two-tailed t-test with Welch's correction comparing CTR versus CTR2 donors and (CTR+CTR2) versus no symptom, symptoms, mild, moderate or severe donors. (C) The percentage of seropositive patients from the different groups were calculated using thresholds obtained in (A-B) 

were represented including sera from COVID-19 patients developing mild (blue, n=22), moderate (green, n=14) and severe (orange, n=15) forms of COVID-19. properties were compared between Spike D614 and G614 variants. (E) Sera from COVID-19 patients developing mild (blue, n=17), moderate (green, n=13) and severe (orange, n=15) forms of COVID-19 were re-evaluated in the SARS-CoV-2 serological assay using Spike D614 and G614 expressing HEK cells. Specific binding of IgG (circles), IgM (squares) and IgA (diamonds) were represented and thresholds (grey boxes) were obtained with the basal levels of Ig binding from control sera tested in Figure 2A . Statistical analysis: unpaired two-tailed t-test with Welch's correction comparing D614 versus G614 conditions. (F) Percentage of patients with decreased seropositivity against D614 and G614 variants from the different groups were presented.

Resource availability -Lead contact: Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Tony Avril (t.avril@rennes.unicancer.fr). Materials availability: This study did not generate new unique reagents. Data and code availability: Data reported in this paper will be shared by the lead contact upon request. This paper does not report original code.

Antibodies, plasmids and other reagents -All antibodies except those specified below were purchased from Jackson Immunoresearch (Ozyme, Saint-Cyr-L'École, France). We also used the rabbit monoclonal anti-SARS-CoV-2 Spike S1 (Sino Biologicals, Clinisciences, Nanterre, (codon GGC at the same position) with the following primers (IDT, Leuven, Belgium): forward 5'-CTTTATCAGGgCGTGAATTGTAC-3' and reverse 5'-AACTGCAACCTGATTACTG-3'. The sequence of the modified plasmid was further verified after complete sequencing (Integragen, Evry, France). Other reagents not specified below were purchased from Sigma-Aldrich.

Human sera collection -The study was carried out according to the regulation of Rennes Biobank (BRIF number: BB-0033-00056) certified as meeting the requirements of NF S96900 for receipt preparation preservation and provision of biological resources. Serum samples were gathered in the SEROCOV collection (DC-2019-3585). Socio-demographic information, underlying medical conditions, history of symptoms back to January 2020, and history of COVID-19 diagnosis before this investigation were collected at the time of the blood test and were presented in Tables 1 and S1 (entitled 'raw & clinical data'). Table S1 is Marquis (Rennes, France) between March 11 th and September 15 th , 2020. All sera were aliquoted and conserved at 4°C for short-term use or frozen at -80°C.

Dulbecco's modified Eagle's medium (Gibco, Thermo Fisher Scientific) supplemented with 10% heat-inactivated fetal bovine serum (FBS) in a 5% CO2 humidified atmosphere at 37°C. For transient overexpression of SARS-CoV-2 transmembrane proteins, HEK cells (10 6 ) were seeded in a 10 cm Petri dish with 10 mL complete medium for 24 hours, and then transfected using calcium phosphate co-precipitation with DNA for 48 hours. Plasmids (10 µg per dish) were J o u r n a l P r e -p r o o f initially diluted with 0.5 mL of CaCl2 (120 mM) and 0.5 mL of HEPES Buffer Saline solution (2x:

HEPES 55 mM, NaCl 274 mM, Na2HPO4 1.4 mM, pH 7.05).

Western blotting -SARS-CoV-2 S, E and M expressing HEK cells were resuspended in ice-cold lysis buffer (composed of 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100) supplemented with protease and phosphatase inhibitor cocktails (Roche, Sigma-Aldrich).

Proteins were resolved by SDS-polyacrylamide gel electrophoresis (12% and 7% polyacrylamide gels for viral E and M proteins, and S proteins respectively) and transferred to Statistical analyses -Graphs and statistical analyses were performed using GraphPad Prism 7.0 software (GraphPad Software). Data are presented as mean ± SD or SEM of at least three independent experiments. Statistical significance (p<0.05 or less) was determined using a paired or unpaired t-test or ANOVA when appropriate. 

SARS-CoV-2 S1 and N-based serological assays reveal rapid seroconversion and induction of specific antibody

A serological assay to detect SARS-CoV-2 seroconversion in humans

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate

The effect of the D614G substitution on the structure of the spike glycoprotein of SARS-CoV-2

D614G Mutation Alters SARS-CoV-2 Spike Conformation and Enhances Protease Cleavage at the S1/S2 Junction

E484K as an innovative phylogenetic event for viral evolution: Genomic analysis of the E484K spike mutation in SARS-CoV-2 lineages from Brazil

A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

The complexities of SARS-CoV-2 serology

Characteristics of SARS-CoV-2 and COVID-19

Global profiling of SARS-CoV-2 specific IgG/ IgM responses of convalescents using a proteome microarray

D614G Spike Variant Does Not Alter IgG, IgM, or IgA Spike Seroassay Performance. medRxiv

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

Antibody profiling and prevalence in US patients during the SARS-CoV2 pandemic

Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays

Large scale genomic analysis of 3067 SARS-CoV-2 genomes reveals a clonal geo-distribution and a rich genetic variations of hotspots mutations

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Serological Approaches for COVID-19: Epidemiologic Perspective on Surveillance and Control

Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom

Geographic and Genomic Distribution of SARS-CoV-2 Mutations

A comprehensive library of fluorescent constructs of SARS-CoV-2 proteins and their initial characterization in different cell types

Multiple Introductions Followed by Ongoing Community Spread of SARS

Exploitation of the Secretory Pathway by SARS-CoV-2 Envelope. bioRxiv

SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates

Diagnostics for SARS-CoV-2 detection: A comprehensive review of the FDA-EUA COVID-19 testing landscape

Performance of nucleocapsid and spike-based SARS-CoV-2 serologic assays

Structural Proteins in Severe Acute Respiratory Syndrome Coronavirus-2

Role of the early secretory pathway in SARS-CoV-2 infection

Emergence and rapid spread of a new severe acute respiratory syndrome

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

SARS-CoV-2 Proteome Microarray for Mapping

Antibody Interactions at Amino Acid Resolution

Inhibition of SARS-CoV-2 viral entry upon blocking N-and O-glycan elaboration

The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity

Dissecting antibody-mediated protection against SARS-CoV-2